Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 2/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL215363 | 0.86 | CTSK (0.36) | CTSKCYP3A4ALDH1A1LMNATDP1 | |
| SCHEMBL27959577 | 0.80 | MAPK1 (0.32) | — | |
| SCHEMBL215503 | 0.80 | CYP3A4 (0.31) | CYP3A4MEN1ALOX15KMT2AALDH1A1 | |
| SCHEMBL217214 | 0.78 | CTSK (0.36) | CTSK | |
| SCHEMBL27826096 | 0.74 | CYP3A4 (0.36) | CYP3A4MEN1ALOX15KMT2AALDH1A1 | |
| SCHEMBL215629 | 0.73 | — | — | |
| SCHEMBL27959574 | 0.72 | ALDH1A1 (0.34) | CYP3A4MEN1ALOX15KMT2AALDH1A1 | |
| SCHEMBL22206798 | 0.72 | LMNA (0.39) | CTSKLMNA | |
| SCHEMBL11864337 | 0.71 | CTSK (0.33) | CTSK | |
| SCHEMBL11876407 | 0.71 | CYP3A4 (0.33) | CYP3A4MEN1ALOX15KMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8088725-B2 | Fragrance compositions and compounds | GIVAUDAN NEDERLAND SERVICES B.V. (NL) | 2012-01-03 | — | — | US | disclosed |
| US-20100132249-A1 | Fragrance Compositions and Compounds | GIVAUDAN NEDERLAND SERVICES B.V. (NL) | 2010-06-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100132249-A1 | Fragrance Compositions and Compounds | H1-0, H1-10, H1-5 | CTSK 4691/4885CYP3A4 1173/4885MEN1 1171/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.